Zimmer Biomet Holdings, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Zimmer Biomet reported adjusted earnings of $1.90 per share for the quarter ended September 30, unchanged from a year earlier and above analysts’ average estimate of $1.88. Revenue rose 3.1% to $2.06 billion, also exceeding the $2.04 billion estimate; reported earnings per share were $1.00 and net income was $191.6 million.

Confirmed

Global impact / market context

Revenue growth and adjusted earnings above expectations suggest the company’s sales and underlying performance held up during the quarter. If that strength continues, it could support cash available for operations and investment; however, reported earnings per share were lower than adjusted earnings, so the measures tell different stories.

Analyst inference

The results modestly exceeded average analyst forecasts, but adjusted earnings were unchanged from last year and analyst estimates had edged down. Shares had gained 9.3% this quarter and 7.9% year to date, while the average analyst rating remained hold, indicating a mixed backdrop.

Analyst inference

What to watch

1. Watch whether revenue growth continues in later quarters; sustained sales gains would indicate the reported increase is more than a one-quarter result. Analyst inference
2. Track the gap between adjusted earnings per share and reported earnings per share, since the article gives $1.90 and $1.00 respectively. Confirmed
3. Analyst estimates had fallen about 0.2% over three months, and one analyst cut an estimate in the last 30 days; further revisions could change expectations. Confirmed

Evidence

• Original source link unavailable